IP Library › Granted Patent US 7,803,808
Granted Patent B2
US 7,803,808 · App. 11/659,936 · Granted Sep 28, 2010

Production of polyketides and other natural products

Assignee: Wyeth LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,803,808
App. No.
11/659,936
Granted
Sep 28, 2010
Kind
B2
Abstract

The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. Therefore in aspect the present invention provides 17-desmethylrapamycin and analogues thereof, methods for their production, including recombinant strains, and isolation and uses of the compounds of the invention. In a further aspect the present invention provides for the use of 17-desmethylrapamycin and analogues thereof in the induction or maintenance of immunosuppression, the stimulation of neuronal regeneration or the treatment of cancer, B-cell malignancies, fungal infections, transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation vascular disease and fibrotic diseases, and in the regulation of wound healing.

Claims (30)

1. A compound having the following formula:

wherein:

x represents a direct bond, —CH 2 —, —S—CH 2 —, —CH 2 —S— or —S(═O)—CH 2 —;

or —CHR 5 -x-CHR 6 — represents

R 1 represents ═O or (H,H);

R 2 represents OH or OMe;

R 3 represents H, OH or OMe;

R 4 represents a structural fragment selected from groups A, B, C, D, E and F,

in which

the wavy line indicates the position of attachment of the fragment,

R 7 represents H or OH and

R 8 represents H, OH, halo, thiol or C 1-4 alkyl;

or R 4 alternatively represents a 5- to 7-membered heterocycle containing one or more heteroatoms selected from the group consisting of O, S and N, which heterocycle is optionally substituted with one or more substituents selected from C 1-4 alkyl, OH, F and Cl; and

R 5 and R 6 are each independently H or OH,

or pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 , wherein R 4 represents a structural fragment selected from the groups A, B, C, E and F, as defined in claim 2 , in which R 7 represents H or OH and R 8 represents H, OH, Cl or F.

3. A compound according to claim 2 , wherein R 4 represents a structural fragment selected from the groups A(i), C(i), E(i) and F(i):

wherein R 7 represents H or OH and R 8 represents H, or OH.

4. A compound according to claim 1 , wherein when R 5 represents OH, R 6 represents H and when R 6 represents OH R 5 represents H.

5. A compound according to claim 1 , wherein x represents a direct bond or CH 2 .

6. A compound according to claim 1 , wherein x represents CH 2 .

7. A compound according to claim 1 , wherein R 2 represents OH.

8. A compound according to claim 1 wherein R 1 represents (H, H), R 2 represents OH, R 3 represents H, R 4 represents the structural fragment C(i), as defined in claim 4 , except that R 7 represents OH and R 8 represents H, and x represents CH 2 .

9. A compound according to claim 1 wherein R 1 represents (H, H) or ═O, R 2 represents OH or OMe, R 3 represents OH or OMe, R 4 represents the structural fragment C(i), as defined in claim 4 , except that R 7 represents OH and R 8 represents H, or OH, and x represents CH 2 .

10. A compound according to claim 1 wherein R 1 represents ═O, R 2 represents OH or OMe, R 3 represents H, OH or OMe, R 4 represents the structural fragment C(i), as defined in claim 4 , except that R 7 represents OH and R 8 represents F or Cl, and x represents CH 2 .

11. A compound according to claim 1 wherein R 1 represents ═O, R 2 represents OH, R 3 represents OMe, R 4 represents the structural fragment C(i), as defined in claim 4 , except that R 7 represents OH and R 8 represents H, and x represents CH 2 .

12. A compound according to claim 1 wherein R 1 represents ═O, R 2 represents OH, R 3 represents OH, R 4 represents the structural fragment C(i), as defined in claim 4 , except that R 7 represents OH and R 8 represents H, and x represents CH 2 .

13. A compound having the following formula:

wherein R 1 represents ═O, R 2 represents OH, R 3 represents OMe, R 4 represents the structural fragment C(i), as defined in claim 4 , except that R 7 represents OH and R 8 represents OMe, and x represents CH 2 .

14. A pharmaceutical composition comprising a compound according to any one of claims 1 - 7 and 8 - 13 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT ASSIGNEE FROM WYETH TO BIOTICA TECHNOLOGY LIMITED PREVIOUSLY RECORDED ON REEL 022120 FRAME 0176. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 27, 2009
From: GREGORY, MATTHEW ALAN; MARTIN, CHRISTINE JANET
To: BIOTICA TECHNOLOGY LIMITED
Reel/Frame 022158/0900 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2009
From: GREGORY, MATTHEW ALAN; MARTIN, CHRISTINE JANET
To: WYETH
Reel/Frame 022120/0176 →
Priority Claims (1)
GB 0417852.1 · Aug 11, 2004 · national
Continuity (1)
Related Publication 20090253732A1 · Oct 8, 2009